24 research outputs found
Recommended from our members
Tetracycline and its Analogues as Drugs Against Protein Aggregation and Amyloid Formation
With more than 20 million cases worldwide, Alzheimer’s disease (AD) is now the most common neurodegenerative disease. The two defining features of this disease are extracellular plaques and intracellular neurofibrillary tangles.
Although no AD treatment is available, researchers are making encouraging progress, including the use of small compounds which interact with amyloid-β (AB) and affect its self aggregation. Tetracyclines (TCs) are thought to have an anti-amyloidogenic effect on Aβ peptides. But the inconsistency of results in literature prompted us to further investigate the behaviour of various fragments of Aβ (Aβ1-40; Aβ1-42; guest-host-peptide Aβ 14-24) which were synthesised as depsi-peptides, in the presence of TCs. Due to their superior solubility the depsi-peptides allowed us to prepare reliable and seed-free stock solutions with reproducible properties. These allowed the preparation of different well-characterised Aβ1-42 species (initial state, oligomers, and fibrils), and to investigate the binding of Aβ ligands (Aβ monomers or TCs) to them or to study the modulation of the kinetics of fibril formation in the absence or presence of TCs, by Surface Plasmon Resonance (SPR), Circular Dichroism (CD) or Thioflavine-T (ThT) fluorescence.
Binding of Aβ1-42 monomers to immobilised fibrils could be well described by the “Dock and Lock” mechanism. TCs do not bind to the prepared Aβ species nor do they alter the highly reproducible kinetics of fibril formation or disaggregated preformed amyloidogenic structures. Consistent with the inactivity of TCs against amyloid β-sheet structures the treatment of APP/PS1tg mice with doxycycline (DC) after plaque formation did not change the plaque load in this mouse model compared to the control mice. These findings suggest that toxic Ap species other than these considered in this study or the common neuroprotection seen for TCs might be responsible for the positive effects in-vivo in previously reported studies
Can Antiviral Activity of Licorice Help Fight COVID-19 Infection?
peer reviewedThe phytotherapeutic properties of Glycyrrhiza glabra (licorice) extract are mainly attributed to glycyrrhizin (GR) and glycyrrhetinic acid (GA). Among their possible pharmacological actions, the ability to act against viruses belonging to different families, including SARS coronavirus, is particularly important. With the COVID-19 emergency and the urgent need for compounds to counteract the pandemic, the antiviral properties of GR and GA, as pure substances or as components of licorice extract, attracted attention in the last year and supported the launch of two clinical trials. In silico docking studies reported that GR and GA may directly interact with the key players in viral internalization and replication such as angiotensin-converting enzyme 2 (ACE2), spike protein, the host transmembrane serine protease 2, and 3-chymotrypsin-like cysteine protease. In vitro data indicated that GR can interfere with virus entry by directly interacting with ACE2 and spike, with a nonspecific effect on cell and viral membranes. Additional anti-inflammatory and antioxidant effects of GR cannot be excluded. These multiple activities of GR and licorice extract are critically re-assessed in this review, and their possible role against the spread of the SARS-CoV-2 and the features of COVID-19 disease is discussed
Gerstmann-Sträussler-Scheinker disease amyloid protein polymerizes according to the "dock-and-lock" model.
Prion protein (PrP) amyloid formation is a central feature of genetic and acquired prion diseases such as Gerstmann-Sträussler-Scheinker disease (GSS) and variant Creutzfeldt-Jakob disease. Themajor component of GSS amyloid is a PrP fragment spanning residues ∼82-146, which when synthesized as a peptide, readily forms fibrils featuring GSS amyloid. The present study employed surface plasmon resonance (SPR) to characterize the binding events underlying PrP82-146 oligomerization at the first stages of fibrillization, according to evidence suggesting a pathogenic role of prefibrillar oligomers rather than mature amyloid fibrils. We followed in real time the binding reactions occurring during short term (seconds) addition of PrP82-146 small oligomers (1-5-mers, flowing species) onto soluble prefibrillar PrP82-146 aggregates immobilized on the sensor surface. SPR data confirmed very efficient aggregation/elongation, consistent with the hypothesis of nucleation-dependent polymerization process. Much lower binding was observed when PrP82-146 flowed onto the scrambled sequence of PrP82-146 or onto prefibrillar Aβ42 aggregates. As previously found with Aβ40, SPR data could be adequately fitted by equations modeling the "dock-and-lock" mechanism, in which the "locking" step is due to sequential conformational changes, each increasing the affinity of the monomerfor the fibril until a condition of irreversible binding is reached. However, these conformational changes (i.e. the locking steps) appear to be faster and easier with PrP82-146 than with Aβ40. Such differences suggest that PrP82-146 has a greater propensity to polymerize and greater stability of the aggregates. © 2006 by The American Society for Biochemistry and Molecular Biology, Inc
In Vitro Aggregation Behavior of a Non-Amyloidogenic λ Light Chain Dimer Deriving from U266 Multiple Myeloma Cells
Excessive production of monoclonal light chains due to multiple myeloma can induce aggregation-related disorders, such as light chain amyloidosis (AL) and light chain deposition diseases (LCDD). In this work, we produce a non-amyloidogenic IgE λ light chain dimer from human mammalian cells U266, which originated from a patient suffering from multiple myeloma, and we investigate the effect of several physicochemical parameters on the in vitro stability of this protein. The dimer is stable in physiological conditions and aggregation is observed only when strong denaturating conditions are applied (acidic pH with salt at large concentration or heating at melting temperature Tm at pH 7.4). The produced aggregates are spherical, amorphous oligomers. Despite the larger β-sheet content of such oligomers with respect to the native state, they do not bind Congo Red or ThT. The impossibility to obtain fibrils from the light chain dimer suggests that the occurrence of amyloidosis in patients requires the presence of the light chain fragment in the monomer form, while dimer can form only amorphous oligomers or amorphous deposits. No aggregation is observed after denaturant addition at pH 7.4 or at pH 2.0 with low salt concentration, indicating that not a generic unfolding but specific conformational changes are necessary to trigger aggregation. A specific anion effect in increasing the aggregation rate at pH 2.0 is observed according to the following order: SO4−≫Cl−>H2PO4−, confirming the peculiar role of sulfate in promoting protein aggregation. It is found that, at least for the investigated case, the mechanism of the sulfate effect is related to protein secondary structure changes induced by anion binding
The Anti-Amyloidogenic Action of Doxycycline: A Molecular Dynamics Study on the Interaction with Aβ42
The pathological aggregation of amyloidogenic proteins is a hallmark of many neurological diseases, including Alzheimer’s disease and prion diseases. We have shown both in vitro and in vivo that doxycycline can inhibit the aggregation of Aβ42 amyloid fibrils and disassemble mature amyloid fibrils. However, the molecular mechanisms of the drug’s anti-amyloidogenic property are not understood. In this study, a series of molecular dynamics simulations were performed to explain the molecular mechanism of the destabilization of Aβ42 fibrils by doxycycline and to compare the action of doxycycline with those of iododoxorubicin (a toxic structural homolog of tetracyclines), curcumin (known to have anti-amyloidogenic activity) and gentamicin (an antibiotic with no experimental evidence of anti-amyloidogenic properties). We found that doxycycline tightly binds the exposed hydrophobic amino acids of the Aβ42 amyloid fibrils, partly leading to destabilization of the fibrillar structure. Clarifying the molecular determinants of doxycycline binding to Aβ42 may help devise further strategies for structure-based drug design for Alzheimer’s disease
Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation
Gelsolin amyloidosis (AGel) is characterized by multiple systemic and ophthalmic features
resulting from pathological tissue deposition of the gelsolin (GSN) protein. To date, no cure is available
for the treatment of any form of AGel. More than ten single-point substitutions in the GSN gene
are responsible for the occurrence of the disease and, among them, D187N/Y is the most widespread
variant. These substitutions undergo an aberrant proteolytic cascade, producing aggregation-prone
peptides of 5 and 8 kDa, containing the Gelsolin Amyloidogenic Core, spanning residues 182–192
(GAC182–192). Following a structure-based approach, we designed and synthesized three novel
sequence-specific peptidomimetics (LB-5, LB-6, and LB-7) built on a piperidine-pyrrolidine unnatural
amino acid. LB-5 and LB-6, but not LB-7, efficiently inhibit the aggregation of the GAC182–192 amyloidogenic
peptides at sub-stoichiometric concentrations. These peptidomimetics resulted also effective
in vivo, in a C. elegans-based assay, in counteracting the proteotoxicity of aggregated GAC182–192.
These data pave the way to a novel pharmacological strategy against AGel and also validate a toolbox
exploitable in other amyloidogenic diseases
Rational Design of a Peptidomimetic Inhibitor of Gelsolin Amyloid Aggregation
Gelsolin amyloidosis (AGel) is characterized by multiple systemic and ophthalmic features resulting from pathological tissue deposition of the gelsolin (GSN) protein. To date, no cure is available for the treatment of any form of AGel. More than ten single-point substitutions in the GSN gene are responsible for the occurrence of the disease and, among them, D187N/Y is the most widespread variant. These substitutions undergo an aberrant proteolytic cascade, producing aggregation-prone peptides of 5 and 8 kDa, containing the Gelsolin Amyloidogenic Core, spanning residues 182–192 (GAC182–192). Following a structure-based approach, we designed and synthesized three novel sequence-specific peptidomimetics (LB-5, LB-6, and LB-7) built on a piperidine-pyrrolidine unnatural amino acid. LB-5 and LB-6, but not LB-7, efficiently inhibit the aggregation of the GAC182–192 amyloidogenic peptides at sub-stoichiometric concentrations. These peptidomimetics resulted also effective in vivo, in a C. elegans-based assay, in counteracting the proteotoxicity of aggregated GAC182–192. These data pave the way to a novel pharmacological strategy against AGel and also validate a toolbox exploitable in other amyloidogenic diseases
Development of a proteolytically stable retro-inverso peptide inhibitor of β-amyloid oligomerization as a potential novel treatment for Alzheimer's disease
The formation of beta-amyloid (Abeta) deposits in the brain is likely to be a seminal step in the development of Alzheimer's disease. Recent studies support the hypothesis that Abeta soluble oligomers are toxic to cells and have potent effects on memory and learning. Inhibiting the early stages of Abeta aggregation could, therefore, provide a novel approach to treating the underlying cause of AD. We have designed a retro-inverso peptide (RI-OR2, H(2)N-